JP2009508521A5 - - Google Patents

Download PDF

Info

Publication number
JP2009508521A5
JP2009508521A5 JP2008532177A JP2008532177A JP2009508521A5 JP 2009508521 A5 JP2009508521 A5 JP 2009508521A5 JP 2008532177 A JP2008532177 A JP 2008532177A JP 2008532177 A JP2008532177 A JP 2008532177A JP 2009508521 A5 JP2009508521 A5 JP 2009508521A5
Authority
JP
Japan
Prior art keywords
vhh
antigen
protein
carrier
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008532177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009508521A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2006/000475 external-priority patent/WO2007035092A2/en
Publication of JP2009508521A publication Critical patent/JP2009508521A/ja
Publication of JP2009508521A5 publication Critical patent/JP2009508521A5/ja
Pending legal-status Critical Current

Links

JP2008532177A 2005-09-23 2006-09-25 タンパク凝集に関連する疾患の診断予防及び治療のためのvhh Pending JP2009508521A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05077180 2005-09-23
PCT/NL2006/000475 WO2007035092A2 (en) 2005-09-23 2006-09-25 Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates

Publications (2)

Publication Number Publication Date
JP2009508521A JP2009508521A (ja) 2009-03-05
JP2009508521A5 true JP2009508521A5 (enExample) 2009-11-05

Family

ID=35700351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008532177A Pending JP2009508521A (ja) 2005-09-23 2006-09-25 タンパク凝集に関連する疾患の診断予防及び治療のためのvhh

Country Status (6)

Country Link
US (1) US20100323905A1 (enExample)
EP (1) EP1934611A2 (enExample)
JP (1) JP2009508521A (enExample)
AU (1) AU2006292871A1 (enExample)
CA (1) CA2622968A1 (enExample)
WO (1) WO2007035092A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0518151A2 (pt) * 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2011049449A1 (en) 2009-10-22 2011-04-28 University Of Twente Vhh for application in tissue repair, organ regeneration, organ replacement and tissue engineering
WO2011107507A1 (en) * 2010-03-03 2011-09-09 Boehringer Ingelheim International Gmbh Biparatopic abeta binding polypeptides
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
EP2873679A1 (en) * 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against amyloid bêta and methods for producing conjugates thereof
US11225514B2 (en) 2017-05-30 2022-01-18 The Regents Of The University Of California Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)
JP7122672B2 (ja) * 2018-06-08 2022-08-22 パナソニックIpマネジメント株式会社 Vhh抗体
CN109206519B (zh) * 2018-09-21 2021-12-03 成都阿帕克生物科技有限公司 一种抗尿素酶b亚单位的纳米抗体及核酸分子和应用
WO2022204793A1 (en) * 2021-03-31 2022-10-06 Kisoji Biotechnology, Inc. Binding agents targeting tumors and/or immune cells
TW202448951A (zh) * 2023-05-17 2024-12-16 美商奧迪希治療公司 經修飾之單域抗體
WO2025133253A2 (en) * 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9813276A (pt) * 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
WO1999037681A2 (en) * 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
AUPR546801A0 (en) * 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
FR2846667B1 (fr) * 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
EP3299393A1 (en) * 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
NZ540771A (en) * 2003-01-10 2009-05-31 Ablynx Nv Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP7221259B2 (ja) 改変した抗体組成物、それを作製および使用する方法
JP2009508521A5 (enExample)
Müller et al. Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain
Omidfar et al. Advances in phage display technology for drug discovery
ES2641294T3 (es) Nuevo anticuerpo para el diagnóstico y/o el pronóstico del cáncer
TWI511742B (zh) 治療性dll4結合蛋白
US20170114149A1 (en) Methods and compositions for in vivo non-covalent linking
JP2014528695A5 (enExample)
IL273196B1 (en) Claudin 6 antibodies and methods of cancer treatment
JP2009517057A5 (enExample)
US20190031770A1 (en) Intercalated single-chain variable fragments
JP2013520174A5 (enExample)
JP2010516747A5 (enExample)
JP2015531768A5 (enExample)
JP6967507B2 (ja) エピトープ選択のための新しい方法
CA2708074A1 (en) Non-aggregating human vh domains
EP3970798A1 (en) Sars-cov-2-nanobodies
JP2009511892A5 (enExample)
CN109563154A (zh) 抗帕多瓦因子ix抗体
JP2008533986A5 (enExample)
JP2008506358A5 (enExample)
CN110642947B (zh) 抗人cd147的单克隆抗体、表达载体、细胞株及其应用
JP4566911B2 (ja) コバラミン分析方法
Gottlin et al. Isolation of novel EGFR-specific VHH domains
Hayes et al. Overcoming antibody expression and screening limitations by smart design: applications to PSA immunoassay development